<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ910501-0142</DOCNO><DOCID>910501-0142.</DOCID><HL>   Technology Brief -- Synergen Inc.:   Firm's Process of Purifying   Human Protein Gets Patent</HL><DATE>05/01/91</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   SYGN SYN</CO><MS>CONSUMER NON-CYCLICAL (NCY)TECHNOLOGY (TEC)</MS><IN>DRUG MANUFACTURERS (DRG)MEDICAL AND BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><RE>CALIFORNIA (CA)COLORADO (CO)</RE><LP>   Synergen Inc. said it received a patent for the process ofpurifying ciliary neurotrophic factor, a human protein thatit hopes to use to help prevent certain nerve damage.   The Boulder, Colo., company received another patent inMarch for the nucleic acid sequences of ciliary neurotrophicfactor.</LP><TEXT>   Synergen, a biotechnology concern, is in a joint venturewith Syntex Inc. to develop a treatment for peripheralneuropathies, damage caused to nerves by diabetes, kidneydisease and cancer treatments. Peripheral neuropathiescurrently aren't treatable.</TEXT></DOC>